Business Description
Valneva SE is a French biotech company founded in 1998 that focuses exclusively on developing and selling vaccines for infectious diseases that currently lack adequate prevention options. The company already markets three approved vaccines targeting Japanese encephalitis, cholera-related diarrhea, and chikungunya, while advancing a broad pipeline of candidates aimed at diseases such as Lyme disease, Zika, shigellosis, and Epstein-Barr virus. Its products reach customers across North America, Europe, and international markets.
